Dr Ken Taylor, CEO of LCT, says, “We are encouraged to see efficacy data at the longer time point. We need to further analyse this encouraging result at future time points to assess NTCELL as a potential treatment for Parkinson’s disease.”
Nice to have a job monitoring till May 2019,,
Ann: NTCELL and Parkinsons trial update, page-4
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 6044404 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1428165 | 3 |
View Market Depth
| Last trade - 16.12pm 14/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |
Day chart unavailable